Towards an Oversampling Method to Improve Hepatocellular Carcinoma Early Prediction

2020 ◽  
pp. 139-148
Author(s):  
Mahbouba Hattab ◽  
Ahmed Maalel ◽  
Henda Hajjami Ben Ghezala
Keyword(s):  
Hepatocellular Carcinoma ◽  
Early Prediction

scholarly journals Identification of New Biomarker for Prediction of Hepatocellular Carcinoma Development in Early-Stage Cirrhosis Patients

2021 ◽  
Vol 2021 ◽  
pp. 1-18
Author(s):  
Gang Ning ◽  
Yongqiang Li ◽  
Wenji Chen ◽  
Wenjuan Tang ◽  
Diwen Shou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
T Cells ◽  
Liver Cirrhosis ◽  
Prognostic Factor ◽  
Cd8 T Cells ◽  
Development Time ◽  
Roc Analysis ◽  
Risk Group ◽  
Early Stage ◽  
Early Prediction

Background. Liver cirrhosis is one of the major drivers of hepatocellular carcinoma (HCC). In the present study, we aimed to identify and validate new biomarker for early prediction of HCC development in early-stage cirrhosis patients. Methods. mRNA expression and clinical parameters of GSE63898, GSE89377, GSE15654, GSE14520, and TCGA-HCC cohort and ICGC-HCC cohort were downloaded for analysis. Wilcoxon test was performed to identify DEGs. Univariate and multivariate Cox regression analysis were used to develop the risk signature, and ROC analysis was performed to analyze the predictive accuracy and sensitivity of the risk signature. Results. There were 42 DEGs (including 28 upregulated genes and 14 downregulated genes) found in early-stage liver cirrhosis patients before developing HCC from GSE1565442. Then, a risk signature consisting of 8 DEGs could effectively classify early-stage cirrhosis patients into high-risk group with shorter HCC development time and low-risk group with longer HCC development time from GSE15654. Multivariate Cox analysis indicated that the risk signature was an independent prognostic factor for the prediction of HCC development and ROC analysis showed that the signature exhibited good predictive efficiency in predicting 2-, 5-, and 10-year HCC development. Mechanistically, significantly higher proportions of CD8 T cells were found to be enriched in cirrhosis patients with low risk score, and higher CD8 T cells were associated with longer HCC development time. Besides, the signature was an independent prognostic factor for poorer prognosis of early-stage liver cirrhosis patients of GSE15654. Moreover, the signature could also separate HCC patients from healthy controls and was also associated with the poorer prognosis of HCC patients from three HCC cohorts. Finally, we also identified HDAC inhibitors, such as trichostatin A, to be a potential chemopreventive treatment for the prevention of HCC development by targeting risk signature based on CMap analysis. Conclusion. A risk signature was developed and validated for early prediction of HCC development, which may be a useful tool to set up individualized follow-up interval schedules.

scholarly journals The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Bo Li ◽  
Boan Li ◽  
Tongsheng Guo ◽  
Zhiqiang Sun ◽  
Xiaohan Li ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Potential Risk ◽  
Hepatic Cirrhosis ◽  
Serum Markers ◽  
Alpha Fetoprotein ◽  
Early Prediction ◽  
Potential Risk Factors ◽  
Golgi Protein ◽  
The Relationship

The early prediction values of diagnostic markers for hepatocellular carcinoma (HCC) are still unclear at present. This study evaluated the prediction value of ten serum markers in HCC. A total of 109 cases of hepatic cirrhosis patients were followed up for 36 months and the relationship between the lifetime risk of developing HCC and levels of serum markers was analyzed. 31.2 (34/109) percent of hepatic cirrhosis patients developed HCC during the study’s timeframe. Higher alpha-fetoprotein (AFP), alpha-fetoprotein-L3 (AFP-L3), alanine aminotransferase (ALT), and AFP-L3/AFP ratio levels are potential risk factors for malignization in hepatic cirrhosis patients (RR=2.99, 2.92, 2.72, and 2.34); serum Golgi protein 73 (GP73) level of hepatic cirrhosis patients decreased significantly after developing HCC (t=2.212;p=0.041). The detection of ALT, AFP, AFP-L3, and GP73 has a certain guiding significance to predict the risk of HCC in hepatic cirrhosis patients.

scholarly journals Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy

Metabolites ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 50 ◽  
Author(s):  
Diren Beyoğlu ◽  
Jeffrey R. Idle
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Liver Diseases ◽  
Large Body ◽  
Disease Diagnosis ◽  
Early Prediction ◽  
Phenyllactic Acid ◽  
Nonalcoholic Fatty Liver ◽  
Major Criterion ◽  
Liver Disease Diagnosis

In recent years, there has been a plethora of attempts to discover biomarkers that are more reliable than α-fetoprotein for the early prediction and prognosis of hepatocellular carcinoma (HCC). Efforts have involved such fields as genomics, transcriptomics, epigenetics, microRNA, exosomes, proteomics, glycoproteomics, and metabolomics. HCC arises against a background of inflammation, steatosis, and cirrhosis, due mainly to hepatic insults caused by alcohol abuse, hepatitis B and C virus infection, adiposity, and diabetes. Metabolomics offers an opportunity, without recourse to liver biopsy, to discover biomarkers for premalignant liver disease, thereby alerting the potential of impending HCC. We have reviewed metabolomic studies in alcoholic liver disease (ALD), cholestasis, fibrosis, cirrhosis, nonalcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH). Specificity was our major criterion in proposing clinical evaluation of indole-3-lactic acid, phenyllactic acid, N-lauroylglycine, decatrienoate, N-acetyltaurine for ALD, urinary sulfated bile acids for cholestasis, cervonoyl ethanolamide for fibrosis, 16α-hydroxyestrone for cirrhosis, and the pattern of acyl carnitines for NAFL and NASH. These examples derive from a large body of published metabolomic observations in various liver diseases in adults, adolescents, and children, together with animal models. Many other options have been tabulated. Metabolomic biomarkers for premalignant liver disease may help reduce the incidence of HCC.

scholarly journals DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study

2018 ◽  
Vol 102 (1) ◽  
Author(s):  
Kazuhiro Saito ◽  
Joseph Ledsam ◽  
Katsutoshi Sugimoto ◽  
Steven Sourbron ◽  
Yoichi Araki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Early Prediction ◽  
Prediction Of Response ◽  
Dce Mri ◽  
Sorafenib Therapy

scholarly journals Efficacy of P2/MS and AFP in Early Prediction of Hepatocellular Carcinoma Recurrence

2020 ◽  
pp. 223-226
Author(s):  
Zeynep Zehra GÜMÜŞ ◽  
Firdevs TOPAL ◽  
Ünal TAŞDEMİR ◽  
Süleyman GÜNAY ◽  
Hakan ÇAMYAR ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Early Prediction ◽  
Hepatocellular Carcinoma Recurrence
Sign in / Sign up

Export Citation Format

Share Document